ATS: First Abx Rx Doesn't Work for ~25% of Pneumonia Cases

Share this content:
ATS: First Abx Rx Doesn't Work for ~25% of Pneumonia Cases
ATS: First Abx Rx Doesn't Work for ~25% of Pneumonia Cases

MONDAY, May 22, 2017 (HealthDay News) -- The first prescription of an antibiotic that the average U.S. adult with pneumonia receives is now ineffective in about a quarter of cases, according to a study presented at the annual meeting of the American Thoracic Society, held from May 19 to 24 in Washington, D.C.

James McKinnell, M.D., an infectious disease specialist at LA BioMed, a California-based research foundation, and colleagues tracked data for 251,947 adults who were prescribed antibiotics to treat community-acquired pneumonia.

The researchers found that 22.1 percent of the patients did not respond to their initial prescription of antibiotic treatment. Patients over the age of 65 were nearly twice as likely to be hospitalized compared to younger patients, after adjusting for other risk factors.

"Our findings suggest that the community-acquired pneumonia treatment guidelines should be updated," McKinnell said in a news release from the American Thoracic Society. Any update should include data on what risk factors leave patients vulnerable to antibiotic failure, he added. "Elderly patients are more vulnerable and should be treated more carefully, potentially with more aggressive antibiotic therapy."

Press Release
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths